1887

Abstract

Two assays (Liaison, Diasorin; IDEIA, Oxoid) for detection of -specific antibodies were compared. A case–control design using patients with neuroborreliosis ( = 48), laboratory defined by a positive -specific antibody index in the spinal fluid, was available and was intended to represent the serological response of disseminated early Lyme borreliosis in general. Serum samples were obtained from 216 Danish blood donors as controls. By comparing sensitivity and specificity using pre-specified cut-off values, significant differences were found. However, using receiver operating characteristic (ROC) curves to optimize and standardize test interpretation, it was shown that testing with both IDEIA IgG and IgM was comparable to testing with Liaison IgG alone by comparing the area under the curve of the diagnostically relevant 25 % partial ROC curve ( = 0.1). When using the Liaison OspC/VlsE IgM assay, the specificity was decreased without a gain in sensitivity. This study proposes standardizing of reporting by using a control population as the reference and choosing decision thresholds guided by the risk of false-positive results at 2 and 8 %. The sensitivities for IDEIA (IgG and IgM combined) were 85 and 95 % and for the Liaison (VlsE IgG) method were 67 and 96 %, respectively. Methods for test evaluation, test interpretation and statistical testing are presented and discussed. In conclusion, Liaison VlsE IgG alone and IDEIA IgG/IgM combined showed a high and comparable discriminatory ability to distinguish serum samples from patients with neuroborreliosis from blood donor controls. However, cut-off values should be adjusted for a proper comparison.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.061275-0
2013-12-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/12/1835.html?itemId=/content/journal/jmm/10.1099/jmm.0.061275-0&mimeType=html&fmt=ahah

References

  1. Aguero-Rosenfeld M. E. 2008; Lyme disease: laboratory issues. Infect Dis Clin North Am 22:301–313, vii [View Article][PubMed]
    [Google Scholar]
  2. Aguero-Rosenfeld M. E., Wang G., Schwartz I., Wormser G. P. 2005; Diagnosis of Lyme borreliosis. Clin Microbiol Rev 18:484–509 [View Article][PubMed]
    [Google Scholar]
  3. Ang C. W., Notermans D. W., Hommes M., Simoons-Smit A. M., Herremans T. 2011; Large differences between test strategies for the detection of anti-Borrelia antibodies are revealed by comparing eight ELISAs and five immunoblots. Eur J Clin Microbiol Infect Dis 30:1027–1032 [View Article][PubMed]
    [Google Scholar]
  4. Bennet R., Lindgren V., Zweygberg Wirgart B. 2008; Borrelia antibodies in children evaluated for Lyme neuroborreliosis. Infection 36:463–466 [View Article][PubMed]
    [Google Scholar]
  5. Bossuyt P. M., Reitsma J. B., Bruns D. E., Gatsonis C. A., Glasziou P. P., Irwig L. M., Lijmer J. G., Moher D., Rennie D., de Vet H. C. Standards for Reporting of Diagnostic Accuracy 2003a; Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 49:1–6 [View Article][PubMed]
    [Google Scholar]
  6. Bossuyt P. M., Reitsma J. B., Bruns D. E., Gatsonis C. A., Glasziou P. P., Irwig L. M., Moher D., Rennie D., de Vet H. C., Lijmer J. G. Standards for Reporting of Diagnostic Accuracy 2003b; The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 49:7–18 [View Article][PubMed]
    [Google Scholar]
  7. Brandenburg A. H., van Dam A. P., Schellekens J. 2011; Problems in comparing test strategies for detection of anti-Borrelia antibodies. Eur J Clin Microbiol Infect Dis 30:1033–1034, author reply 1035–1037 [View Article][PubMed]
    [Google Scholar]
  8. Burbelo P. D., Issa A. T., Ching K. H., Cohen J. I., Iadarola M. J., Marques A. 2010; Rapid, simple, quantitative, and highly sensitive antibody detection for Lyme disease. Clin Vaccine Immunol 17:904–909 [View Article][PubMed]
    [Google Scholar]
  9. Busson L., Reynders M., Van den Wijngaert S., Dahma H., Decolvenaer M., Vasseur L., Vandenberg O. 2012; Evaluation of commercial screening tests and blot assays for the diagnosis of Lyme borreliosis. Diagn Microbiol Infect Dis 73:246–251 [View Article][PubMed]
    [Google Scholar]
  10. Cerar T., Ruzic-Sabljic E., Cimperman J., Strle F. 2006; Comparison of immunofluorescence assay (IFA) and LIAISON in patients with different clinical manifestations of Lyme borreliosis. Wien Klin Wochenschr 118:686–690 [View Article][PubMed]
    [Google Scholar]
  11. Cerar T., Ogrinc K., Strle F., Ruzić-Sabljić E. 2010; Humoral immune responses in patients with Lyme neuroborreliosis. Clin Vaccine Immunol 17:645–650 [View Article][PubMed]
    [Google Scholar]
  12. Dessau R. B., Bangsborg J. M., Ejlertsen T., Skarphedinsson S., Schønheyder H. C. 2010a; Utilization of serology for the diagnosis of suspected Lyme borreliosis in Denmark: survey of patients seen in general practice. BMC Infect Dis 10:317 [View Article][PubMed]
    [Google Scholar]
  13. Dessau R. B., Ejlertsen T., Hilden J. 2010b; Simultaneous use of serum IgG and IgM for risk scoring of suspected early Lyme borreliosis: graphical and bivariate analyses. APMIS 118:313–323 [View Article][PubMed]
    [Google Scholar]
  14. Dessau R. B., Eliasson I., Skarpaas T., Nyman D. 2011; Report from a survey of laboratory methods used in Scandinavia. Testing for Lyme borreliosis in the Nordic countries – variations in strategies and rate of seropositivity. http://www.dskm.dk/pdf/rapporter/Serological%20testing%20for%20Lyme.pdf
    [Google Scholar]
  15. Ekerfelt C., Ernerudh J., Forsberg P., Jonsson A. L., Vrethem M., Arlehag L., Forsum U. 2004; Lyme borreliosis in Sweden – diagnostic performance of five commercial Borrelia serology kits using sera from well-defined patient groups. APMIS 112:74–78 [View Article][PubMed]
    [Google Scholar]
  16. Fletcher R. H., Fletcher S. W., Wagner E. H. 1996; Diagnosis. In Clinical Epidemiology. The Essentials 3rd edn pp. 43–74 Baltimore: Williams & Wilkins;
    [Google Scholar]
  17. Habbema J. D. F., Eijkemans R., Krijnen P., Knottnerus J. A. 2002; Analysis of data on the accuracy of diagnostic tests. In The Evidence Base of Clinical Diagnosis pp. 117–143 Edited by Knottnerus J. A. London: BMJ Books;
    [Google Scholar]
  18. Hansen K. 1994; Lyme neuroborreliosis: improvements of the laboratory diagnosis and a survey of epidemiological and clinical features in Denmark 1985–1990. Acta Neurol Scand Suppl 151:1–44[PubMed] [CrossRef]
    [Google Scholar]
  19. Hansen K., Lebech A. M. 1991; Lyme neuroborreliosis: a new sensitive diagnostic assay for intrathecal synthesis of Borrelia burgdorferi-specific immunoglobulin G, A, and M. Ann Neurol 30:197–205 [View Article][PubMed]
    [Google Scholar]
  20. Hansen K., Lebech A. M. 1992; The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985–1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. Brain 115:399–423 [View Article][PubMed]
    [Google Scholar]
  21. Hansen K., Hindersson P., Pedersen N. S. 1988; Measurement of antibodies to the Borrelia burgdorferi flagellum improves serodiagnosis in Lyme disease. J Clin Microbiol 26:338–346[PubMed]
    [Google Scholar]
  22. Hansen K., Pii K., Lebech A. M. 1991; Improved immunoglobulin M serodiagnosis in Lyme borreliosis by using a mu-capture enzyme-linked immunosorbent assay with biotinylated Borrelia burgdorferi flagella. J Clin Microbiol 29:166–173[PubMed]
    [Google Scholar]
  23. Hjelm F., Carlsson F., Getahun A., Heyman B. 2006; Antibody-mediated regulation of the immune response. Scand J Immunol 64:177–184 [View Article][PubMed]
    [Google Scholar]
  24. Huang Y., Pepe M. S. 2009; Biomarker evaluation and comparison using the controls as a reference population. Biostatistics 10:228–244 [View Article][PubMed]
    [Google Scholar]
  25. Hunfeld K.-P., Fingerle V., Stanek G., Daghofer E., Brade V., Wilske B., Peters H. 2005; European multicenter study for evaluation of a new enzyme immunoassay for detection of IgG antibodies against Borrelia burgdorferi sensu lato . In 10th International Conference on Lyme Borreliosis and Other Tick-borne Diseases 11–15 September Vienna: Austria. Poster presentation;
    [Google Scholar]
  26. Huppertz H. I., Bentas W., Haubitz I., Girschick H. J., Ganser G., Thon A., Suschke H. J., Schauer-Petrowskaja C., Minden K., Schuchmann L. 1998; Diagnosis of paediatric Lyme arthritis using a clinical score. Eur J Pediatr 157:304–308 [View Article][PubMed]
    [Google Scholar]
  27. Lebech A. M., Hansen K., Brandrup F., Clemmensen O., Halkier-Sørensen L. 2000; Diagnostic value of PCR for detection of Borrelia burgdorferi DNA in clinical specimens from patients with erythema migrans and Lyme neuroborreliosis. Mol Diagn 5:139–150[PubMed] [CrossRef]
    [Google Scholar]
  28. Marangoni A., Sambri V., Accardo S., Cavrini F., Mondardini V., Moroni A., Storni E., Cevenini R. 2006; A decrease in the immunoglobulin G antibody response against the VlsE protein of Borrelia burgdorferi sensu lato correlates with the resolution of clinical signs in antibiotic-treated patients with early Lyme disease. Clin Vaccine Immunol 13:525–529 [View Article][PubMed]
    [Google Scholar]
  29. Marangoni A., Moroni A., Accardo S., Cevenini R. 2008; Borrelia burgdorferi VlsE antigen for the serological diagnosis of Lyme borreliosis. Eur J Clin Microbiol Infect Dis 27:349–354 [View Article][PubMed]
    [Google Scholar]
  30. Müller I., Freitag M. H., Poggensee G., Scharnetzky E., Straube E., Schoerner C., Hlobil H., Hagedorn H. J., Stanek G. other authors 2012; Evaluating frequency, diagnostic quality, and cost of Lyme borreliosis testing in Germany: a retrospective model analysis. Clin Dev Immunol 2012: Article, ID 595427 [View Article][PubMed]
    [Google Scholar]
  31. Pepe M. S. 2003a; Comparing binary tests and regression analysis. In The Statistical Evaluation of Medical Tests for Classification and Prediction pp. 35–65 Oxford: Oxford University Press;
    [Google Scholar]
  32. Pepe M. S. 2003b; The receiver operating characteristic curve. In The Statistical Evaluation of Medical Tests for Classification and Prediction pp. 66–95 Oxford: Oxford University Press;
    [Google Scholar]
  33. Pepe M. S., Longton G., Janes H. 2009; Estimation and comparison of receiver operating characteristic curves. Stata J 9:1–16[PubMed]
    [Google Scholar]
  34. Petersen E., Tolstrup M., Capuano F., Ellermann-Eriksen S. 2008; Population-based study of diagnostic assays for Borrelia infection: comparison of purified flagella antigen assay (Ideia™, Dako Cytomation) and recombinant antigen assay (Liaison®, DiaSorin). BMC Clin Pathol 8:4 [View Article][PubMed]
    [Google Scholar]
  35. Porwancher R. B., Hagerty C. G., Fan J., Landsberg L., Johnson B. J., Kopnitsky M., Steere A. C., Kulas K., Wong S. J. 2011; Multiplex immunoassay for Lyme disease using VlsE1-IgG and pepC10-IgM antibodies: improving test performance through bioinformatics. Clin Vaccine Immunol 18:851–859 [View Article][PubMed]
    [Google Scholar]
  36. R Development Core Team 2012 R: A Language and Environment for Statistical Computing Vienna, Austria: R Foundation for Statistical Computing;
    [Google Scholar]
  37. Riesbeck K., Hammas B. 2007; Comparison of an automated Borrelia indirect chemiluminescent immunoassay (CLIA) with a VlsE/C6 ELISA and immunoblot. Eur J Clin Microbiol Infect Dis 26:517–519 [View Article][PubMed]
    [Google Scholar]
  38. Robertson J., Guy E., Andrews N., Wilske B., Anda P., Granström M., Hauser U., Moosmann Y., Sambri V. other authors 2000; A European multicenter study of immunoblotting in serodiagnosis of Lyme borreliosis. J Clin Microbiol 38:2097–2102[PubMed]
    [Google Scholar]
  39. Robin X., Turck N., Hainard A., Tiberti N., Lisacek F., Sanchez J. C., Muller M. 2011; pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12:77 [View Article][PubMed]
    [Google Scholar]
  40. Sackett D. L., Haynes R. B. 2002; The architecture of diagnostic research. BMJ 324:539–541 [View Article][PubMed]
    [Google Scholar]
  41. Stanek G., Fingerle V., Hunfeld K. P., Jaulhac B., Kaiser R., Krause A., Kristoferitsch W., O’Connell S., Ornstein K. other authors 2011; Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 17:69–79 [View Article][PubMed]
    [Google Scholar]
  42. Stanek G., Wormser G. P., Gray J., Strle F. 2012; Lyme borreliosis. Lancet 379:461–473 [View Article][PubMed]
    [Google Scholar]
  43. Tjernberg I., Krüger G., Eliasson I. 2007; C6 peptide ELISA test in the serodiagnosis of Lyme borreliosis in Sweden. Eur J Clin Microbiol Infect Dis 26:37–42 [View Article][PubMed]
    [Google Scholar]
  44. Verkaik N. J., Boelens H. A., de Vogel C. P., Tavakol M., Bode L. G., Verbrugh H. A., van Belkum A., van Wamel W. J. 2010; Heterogeneity of the humoral immune response following Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 29:509–518 [View Article][PubMed]
    [Google Scholar]
  45. Wagner B., Freer H., Rollins A., Erb H. N. 2011; A fluorescent bead-based multiplex assay for the simultaneous detection of antibodies to B. burgdorferi outer surface proteins in canine serum. Vet Immunol Immunopathol 140:190–198 [View Article][PubMed]
    [Google Scholar]
  46. Wormser G. P., Schriefer M., Aguero-Rosenfeld M. E., Levin A., Steere A. C., Nadelman R. B., Nowakowski J., Marques A., Johnson B. J., Dumler J. S. 2013; Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis 75:9–15 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.061275-0
Loading
/content/journal/jmm/10.1099/jmm.0.061275-0
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error